Claims for Patent: 6,308,714

Summary for Patent: 6,308,714

Title:	Ultrasound enhanced chemotherapy
Abstract:	Apparatus and method is provided for enhancing the action of anti-cancer agents, which includes the introduction of anti-cancer agent into or proximate a tumor within a body and thereafter introducing ultrasonic energy at the solid tumor with the introduced anti-cancer agent. The ultrasonic energy is sufficient to increase the anti-cancer activity on the solid tumor without significant heating of the solid tumor or surrounding tissue.
Inventor(s):	Peterson; Thomas M. (Erie, PA), Siegel; Robert J. (Venice, CA)
Assignee:	Coraje, Inc. (San Francisco, CA)
Application Number:	09/189,608
Patent Claims:	1. A method of anti-cancer drug delivery comprising the steps of: introducing an anti-cancer drug into a solid tumor within a body; and transcutaneous introducing ultrasonic energy into the solid tumor while the anti-cancer drug is present therein, the ultrasonic energy being less than about 100 kHz at less than about 50 watts in order to prevent heating of the tumor. 2. The method according to claim 1 wherein the ultrasonic energy is introduced by a catheter. 3. The method according to claim 1 wherein the ultrasonic energy is introduced transcutaneously. 4. The method according to claim 1 wherein the ultrasonic energy is introduced with sufficient energy and frequency to cause vasodilation within the tumor. 5. The method according to claim 1 wherein the anti-cancer drug is selected from the group consisting of alkylating agents, agents with alkylator activity, antimelabolites, anti-tumor antibiotics, plant alkaloids, enzymes, hormonal agents and anti-angiogenesis agents. 6. The method according to claim 1 wherein said anti-cancer agent is selected from the group consisting of: Adriamycin, Alkeran, AntiVEGF monoclonal antibody SU5416, Aredia, Arimidex, BiCNU, Bleomycin, Blenoxane, Camptosar, Casodex, CeeNU, Celestone, CM101 Soluspan Suspension, CA1, Cerubidine, Cisplatin, Cosmegan, Cytosar U, Cytoxan, Daunorubricin, DaunoXome, Depo-Provera Sterile Aqueous Suspension, Didronel, Diethylstilbestrol, Diflucan, Doxil, Doxorubicin Hydrochloride, DTIC-Dome, Elspar, Emcyt, Epogen, Ergamisol, Ethyol, Etopophos, Etoposide, Eulexin, Femara, Fludara, Fluorouracil, Gemzar, Gliade, Hexalen, Hycamtin, Hydrea, Hydroxyurea, Idamycin, Iflex, Intron A, Kytril, Leucovorin Calcium, Leukeran, Leukine, Leustatin, Lupron, Lysodren, Marinol, Matulane, Mesnex, Methotrexate Sodium, Mithracin, Mitoxantrosc, Mustargen, Mutamycin, Myleran, Navelbine, Neupogen, Nilandron, Nipent, Nolvadex, Novantrone, Oncaspar, Oncovin, Paraplatin, Photofrin, Platinol, Procrit, Proleukin, Purinethol, Roferon A, Rubex, Salagen, Sandostatin, Squalamine, Sterile FUDR, Taxol, Taxotere, Teslac, Thalidomide, TheraCys BCG, Thioguanine, Thioplex, Tice BCG, TNP 470, Velban, Vesanoid, VePesid, Vitaxin, Vumon, Zanosar, Zinecard, Zofran, Zoladex, Zyloprim, 2 Methoxy-oestradiol. 7. The method according to claim 1 wherein the step of introducing an anti-cancer drug includes incorporating the anti-cancer drug into microbubbles before introduction into the tumor. 8. The method according to claim 1 further comprising the step of introducing microbubbles into the tumor with the anti-cancer drug. 9. A method of anti-cancer drug delivery comprising the steps of: introducing an anti-cancer drug proximate cancer cells; and promoting intracellular activation by irradiating the cancer cells with ultrasound to cause passage of the anti-cancer drug into the cancer cells, the ultrasound having the energy of less than about 50 watts and a frequency of less than 100 kHz in order to prevent heating of the cancer cell. 10. The method according to claim 9 wherein the ultrasonic energy is introduced by a catheter. 11. The method according to claim 9 wherein the ultrasonic energy is introduced transcutaneously. 12. The method according to claim 9 wherein the step of introducing an anti-cancer drug includes incorporating the anti-cancer drug into microbubbles before introduction proximate cancer cells. 13. The method according to claim 9 further comprising the step of introducing microbubbles proximate the cancer cells with the anti-cancer drug. 14. A method for enhancing the action of an anti-cancer agent in the treatment of a solid tumor, said method comprising the steps of: introducing an anti-cancer agent into a solid tumor within a body; and introducing ultrasonic energy into the solid tumor, said ultrasonic energy being of sufficient energy to increase the anti-cancer activity of the agent on the solid tumor without significant heating of the solid tumor or surrounding tissue, said ultrasonic energy being less than about 100 kHz at less than about 50 watts in order to prevent heating of the tumor. 15. The method according to claim 14 wherein the ultrasonic energy is introduced by a catheter. 16. The method according to claim 14 wherein the ultrasonic energy is introduced transcutaneously. 17. The method according to claim 14 wherein the ultrasonic energy is introduced with sufficient energy and frequency to cause vasodilation within the tumor. 18. The method according to claim 14 wherein the anti-cancer drug is selected from the group consisting of alkylating agents, agents with alkylator activity, antimelabolites, anti-tumor antibiotics, plant alkaloids, enzymes, hormonal agents and anti-angiogenesis agents. 19. The method according to claim 14 wherein said anti-cancer agent is selected from the group consisting of: Adriamycin, Alkeran, AntiVEGF monoclonal antibody SU5416, Aredia, Arimidex, BiCNU, Bleomycin, Blenoxane, Camptosar, Casodex, CeeNU, Celestone, CM101 Soluspan Suspension, CA1, Cerubidine, Cisplatin, Cosmegan, Cytosar U, Cytoxan, Daunorubricin, DaunoXome, Depo-Provera Sterile Aqueous Suspension, Didronel, Diethylstilbestrol, Diflucan, Doxil, Doxorubicin Hydrochloride, DTIC-Dome, Elspar, Emcyt, Epogen, Ergamisol, Ethyol, Etopophos, Etoposide, Eulexin, Femara, Fludara, Fluorouracil, Gemzar, Gliade, Hexalen, Hycamtin, Hydrea, Hydroxyurea, Idamycin, Iflex, Intron A, Kytril, Leucovorin Calcium, Leukeran, Leukine, Leustatin, Lupron, Lysodren, Marinol, Matulane, Mesnex, Methotrexate Sodium, Mithracin, Mitoxantrosc, Mustargen, Mutamycin, Myleran, Navelbine, Neupogen, Nilandron, Nipent, Nolvadex, Novantrone, Oncaspar, Oncovin, Paraplatin, Photofrin, Platinol, Procrit, Proleukin, Purinethol, Roferon A, Rubex, Salagen, Sandostatin, Squalamine, Sterile FUDR, Taxol, Taxotere, Teslac, Thalidomide, TheraCys BCG, Thioguanine, Thioplex, Tice BCG, TNP 470, Velban, Vesanoid, VePesid, Vitaxin, Vumon, Zanosar, Zinecard, Zofran, Zoladex, Zyloprim, 2 Methoxy-oestradiol. 20. The method according to claim 15 wherein the step of introducing an anti-cancer drug includes incorporating the anti-cancer drug into microbubbles before introduction into the tumor. 21. The method according to claim 15 further comprising the step of introducing microbubbles into the tumor with the anti-cancer drug. 22. A method for inhibiting the sequence of angiogenesis of cancer cells in a tumor, the method comprising the steps of: transcutaneous introducing an antiangiogenesis agent proximate the cancer cells within the tumor; and introducing ultrasonic energy into the tumor while the antiangiogeneses agent is present therein, the ultrasonic energy being less than 100 kHz at less that 50 watts in order to prevent heating of the tumor. 23. The method according to claim 1 wherein the ultrasonic energy is introduced in a planar non-focused manner. 24. The method according to claim 9 wherein the cancer cells are eradiated with planar non-focused ultrasound. 25. The method according to claim 14 wherein the ultrasonic energy is introduced in a planar non-focused manner. 26. The method according to claim 22 wherein the ultrasonic energy is introduced in a planar non-focused manner. 27. The method according to claim 22 wherein the step of introducing an anti-cancer drug includes incorporating the anti-cancer drug into microbubbles before introduction proximate the cancer cells within the tumor. 28. The method according to claim 22 further comprising the step of introducing microbubbles proximate the cancer cells within the tumor with the anti-cancer drug.

Details for Patent 6,308,714

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26